|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||228.33 - 229.66|
|52 Week Range||183.75 - 229.66|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.25%|
In June 2017, the FDA accepted Bioverativ’s investigative new drug application for BIVV001, a drug designed to treat prophylaxis from bleeding associated with hemophilia A.
The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).
Skechers, which released its 2Q17 results on July 20, 2017, reported earnings per share of $0.38. The company missed analysts' consensus expectation by a margin of $0.06.
On March 23, 2015, the FDA approved Abiomed’s Impella 2.5 heart pump as a temporary ventricular support device.
For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.
In 1Q17, Align Technology (ALGN) also witnessed a robust rise of around 45.2% in volumes of Invisalign sold in Asia-Pacific markets on a YoY basis.
For 1Q17, Align Technology (ALGN) reported revenues close to $310.3 million, which represents YoY (year-over-year) growth of around 30.0%.
Domino's better-than-expected SSSG and earnings in 1Q17 appear to have increased investor confidence, leading to rises in DPZ stock and its PE multiple.
The Zacks Analyst Blog Highlights: iShares Core S&P Mid-Cap ETF, iShares Russell Mid-Cap ETF, Vanguard Mid-Cap Growth ETF, iShares S&P Mid-Cap 400 Growth ETF and Schwab U.S. Mid-Cap ETF
Mid-cap ETFs are arguably safer options and have the potential to move higher in turbulent times, especially if political issues or financial instability creeps into the picture.
As of April 5, 2017, Panera was trading at a forward PE multiple of 38.8x—compared to 32.6x before the acquisition rumor started to surface on April 3.